author-photo

Ruth Z. Rutledge

Merck & Co.

6

Papers

3910

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (3733)
127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (58)
A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

2008 Clinical and Vaccine Immunology
Show All
- Source
- Cite
- Save
Citations (52)
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

2006 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (48)